Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
3 evidence topics · 2 sources
Selective inhibition of aldosterone synthase (CYP11B2)
“Lorundrostat is a novel molecular entity (Figure 1) designed to target the renin–angiotensin–aldosterone system (RAAS), via inhibition of aldosterone synthase (CYP11B2) resulting in targeted suppression of aldosterone production.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aldosterone synthase (CYP11B2) is a mitochondrial cytochrome P450 (CYP) enzyme that converts 11‐deoxycorticosterone (11‐DOC) to aldosterone in three consecutive steps” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
In vitro potency and selectivity over 11β-hydroxylase (CYP11B1)
“Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduction of circulating aldosterone compared with mineralocorticoid receptor antagonists
“In contrast to mineralocorticoid receptor antagonists (MRAs), lorundrostat is designed to reduce rather than stimulating the substantial increase in circulating aldosterone seen with MRAs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This unique difference is anticipated to reduce adverse non‐MR‐mediated aldosterone signaling via the GPER (GPR30) receptor on blood vessels and other tissues, avoiding the estrogenic side effects of MRAs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote